Arbutus Biopharma Corp (ABUS): Long-Term Debt
$0
As of 2025-12-31
$0
As of 2026-06-30
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | n/a | 2026-03-23, Balance as of period end |
| 2024-12-31 | $0 | n/a | 2025-03-27, Balance as of period end |
| 2023-12-31 | $0 | n/a | 2024-03-05, Balance as of period end |
| 2022-12-31 | $0 | n/a | 2023-03-02, Balance as of period end |
| 2021-12-31 | $0 | n/a | 2022-03-03, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $0 | n/a |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $1.65M | n/a |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2024-12-31 | $8.65M | -21.4% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $27.13M | -6.3% |
| uniQure N.V. (QURE) | 2025-12-31 | $71.92M | +8.9% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $93.17M | n/a |
| BioAge Labs, Inc. (BIOA) | 2024-12-31 | $8.50M | n/a |
| Verastem, Inc. (VSTM) | 2024-12-31 | $40.72M | +1.6% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $0 | -100.0% |
Compare ABUS, CVSI, TNXP, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗